Vitamin D Level in Recurrent PV

Sponsor

Kasr El Aini Hospital (Other)

Overall Status

Recruiting

CT.gov ID

NCT05067699

Collaborator

(none)

200

Enrollment

Location

5.9

Anticipated Duration (Months)

33.6

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Serum Samples will be taken from patients with recurrent Pityriasis Versicolor for the evaluation of vitamin D level.

Condition or Disease	Intervention/Treatment	Phase
Recurrent Pityriasis Versicolor	Diagnostic Test: Human 25-Hydroxyvitamin D3 (HVD3) ELISA Kit (96 well)

Study Design

Study Type:

Observational

Anticipated Enrollment :

200 participants

Observational Model:

Case-Control

Time Perspective:

Prospective

Official Title:

Serum Vitamin D Level Detection in Patients With Recurrent Pityriasis Versicolor

Actual Study Start Date :

Sep 1, 2021

Anticipated Primary Completion Date :

Jan 1, 2022

Anticipated Study Completion Date :

Mar 1, 2022

Arms and Interventions

Arm	Intervention/Treatment
Patients recurrent pityriasis versicolor	Diagnostic Test: Human 25-Hydroxyvitamin D3 (HVD3) ELISA Kit (96 well) The serum will be tested by a double-antibody sandwich enzyme-linked immunosorbent assay (ELISA) to assay the level of Human 25Dihydroxy vitamin D（25-OH-D).
Controls Healthy age and sex matched	Diagnostic Test: Human 25-Hydroxyvitamin D3 (HVD3) ELISA Kit (96 well) The serum will be tested by a double-antibody sandwich enzyme-linked immunosorbent assay (ELISA) to assay the level of Human 25Dihydroxy vitamin D（25-OH-D).

Arm

Intervention/Treatment

Patients

recurrent pityriasis versicolor

Diagnostic Test: Human 25-Hydroxyvitamin D3 (HVD3) ELISA Kit (96 well)

The serum will be tested by a double-antibody sandwich enzyme-linked immunosorbent assay (ELISA) to assay the level of Human 25Dihydroxy vitamin D（25-OH-D).

Controls

Healthy age and sex matched

Diagnostic Test: Human 25-Hydroxyvitamin D3 (HVD3) ELISA Kit (96 well)

The serum will be tested by a double-antibody sandwich enzyme-linked immunosorbent assay (ELISA) to assay the level of Human 25Dihydroxy vitamin D（25-OH-D).

Outcome Measures

Primary Outcome Measures

Serum 25(OH) D3 level [6months-1 year]
The serum of patients and controls will be tested by a double-antibody sandwich enzyme-linked immunosorbent assay (ELISA) to assay the level of Human 25Dihydroxy vitamin D（25-OH-D).

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 60 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

- Patients with recurrent pityriasis versicolor (active now) and not taking treatment for it.
Patients of both genders.
Age ≥18 years old.

Exclusion Criteria:

- Patients with other cutaneous diseases.
Patient's having dandruff (scaly scalp) even if not symptomatizing.
Pregnant and lactating females, children, prisoners, cognitively impaired or mentally disabled subjects.
Patients with autoimmune diseases.
Patients with immunodeficiency diseases.
Immunosuppressed patients e.g. HIV, diabetics, organ transplant, malignancy, patients taking immunosuppressive drugs e.g. chemotherapy, cortisone.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Kasr Al Ainy Teaching Hospital	Cairo		Egypt

Sponsors and Collaborators

Kasr El Aini Hospital

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

Responsible Party:

Rana F Hilal, MD, Lecturer of Dermatology, faculty of Medicine, Cairo University., Kasr El Aini Hospital

ClinicalTrials.gov Identifier:

NCT05067699

Other Study ID Numbers:

VitD&PV

First Posted:

Oct 5, 2021

Last Update Posted:

Oct 5, 2021

Last Verified:

Sep 1, 2021

Additional relevant MeSH terms:

Tinea Versicolor

Pityriasis

Recurrence

Hydroxycholecalciferols

Calcifediol

Study Results

No Results Posted as of Oct 5, 2021